ALK and non-small cell lung carcinoma: The ALCHEMIST trial also has an ALK-rearranged arm, in addition to an EGFR-mutated arm, primarily looking at improved DFS with TKIs (crizotinib and erlotinib, respectively) vs. placebo in patients with stage IB-IIIA, resected NSCLC that have also completed adjuvant standard of care treatment (71).